More on Raptor Pharmaceutical (RPTP): Q4 EPS misses estimates by a large margin, and are down 28% from the same quarter last year. R&D expenses increased nearly 50% to $9M, driven largely by higher product manufacturing costs for RP103, its treatment for cystinosis, Huntington's disease and non-alcoholic steatohepatitis, plus other supporting study expenses and employee compensation. SG&A costs also ramped up during the quarter due to marketing expenses attributed to RP103 as well.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Mon, 12:48PM)
at Investor's Business Daily (Jan 6, 2015)
at Investor's Business Daily (Jan 5, 2015)
at Nasdaq.com (Dec 29, 2014)
at CNBC.com (Mar 13, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs